Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Amortization - Intangibles (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Amortization - Intangibles for 16 consecutive years, with $850000.0 as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles fell 32.38% to $850000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 23.37% year-over-year, with the annual reading at $4.0 million for FY2025, 23.37% down from the prior year.
  • Amortization - Intangibles for Q4 2025 was $850000.0 at Harvard Bioscience, down from $855000.0 in the prior quarter.
  • The five-year high for Amortization - Intangibles was $1.6 million in Q4 2022, with the low at $850000.0 in Q4 2025.
  • Average Amortization - Intangibles over 5 years is $1.3 million, with a median of $1.4 million recorded in 2023.
  • The sharpest move saw Amortization - Intangibles grew 13.19% in 2022, then tumbled 35.91% in 2025.
  • Over 5 years, Amortization - Intangibles stood at $1.4 million in 2021, then increased by 13.19% to $1.6 million in 2022, then decreased by 14.91% to $1.4 million in 2023, then decreased by 9.37% to $1.3 million in 2024, then plummeted by 32.38% to $850000.0 in 2025.
  • According to Business Quant data, Amortization - Intangibles over the past three periods came in at $850000.0, $855000.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.